Journal article
Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age
- Abstract:
-
Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a ‘toddler’ booster dose are essential to optimise vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vacc... Expand abstract
- Publication status:
- Accepted
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Novartis Vaccines and Diagnostics
More from this funder
Bibliographic Details
- Publisher:
- Lippincott, Williams and Wilkins Publisher's website
- Journal:
- Pediatric Infectious Disease Journal Journal website
- Publication date:
- 2015-01-01
- DOI:
- ISSN:
-
1532-0987
Item Description
- Pubs id:
-
pubs:574337
- UUID:
-
uuid:6dc5c441-f1a6-410c-8de9-fcd457da57b2
- Local pid:
- pubs:574337
- Source identifiers:
-
574337
- Deposit date:
- 2015-11-17
Terms of use
- Copyright date:
- 2015
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record